drugset / Trial / NCT06281704
A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and efficacy of AK101 in subjects with moderately to severely active ulcerative colitis.
Timeline
- Start
- 2020-11-26
- Primary completion
- 2022-05-17
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBDAROKIMAB | Monoclonal antibody | — | Intravenous |